Sign in

    Dennis Panelo

    Research Analyst at Laven Partners

    Dennis Panelo is an analyst at Laven Partners, specializing in regulatory compliance and fund management services for investment firms. While specific companies covered by Panelo are not publicly listed, his focus includes regulatory hosting and appointed representative platforms for asset management clients, primarily in the UK and Europe. Details of his performance track record, including rankings or returns generated, as well as precise career milestones and prior experience, remain unavailable in public sources. Panelo operates under the regulated framework of Laven Advisors LLP, which is authorized and regulated by the UK's Financial Conduct Authority, but no individual securities licenses or FINRA registrations can be confirmed.

    Dennis Panelo's questions to Quoin Pharmaceuticals (QNRX) leadership

    Dennis Panelo's questions to Quoin Pharmaceuticals (QNRX) leadership • Q3 2023

    Question

    The analyst asked about the total addressable market (TAM) for the Netherton syndrome product and questioned why Quoin, with its low valuation relative to cash, is not an acquisition target itself.

    Answer

    The executive estimated the total market opportunity to be substantially in excess of $500 million. Regarding a potential acquisition of Quoin, the executive acknowledged the company's attractive position but stated that such matters would be handled by the Board of Directors while management remains focused on execution.

    Ask Fintool Equity Research AI